Ignis Therapeutics announced that Solriamfetol Hydrochloride Tablets received approval from China’s National Medical Products Administration (NMPA) for improving wakefulness in adult patients with obstructive sleep apnea (OSA) accompanied by excessive daytime sleepiness (EDS).
Contents
Regulatory Approval & Product Profile
| Attribute | Details |
|---|---|
| Company | Ignis Therapeutics |
| Product | Solriamfetol Hydrochloride Tablets |
| Approval | NMPA (China) |
| Indication | OSA with EDS in adult patients |
| Mechanism | Dual dopamine (DA) and norepinephrine (NE) reuptake inhibition |
| Global Status | Already approved in Europe and US for OSA-EDS and narcolepsy |
Clinical Efficacy: TONES Studies & Chinese Phase 3
| Efficacy Parameter | Result | Clinical Significance |
|---|---|---|
| Onset of Action | Within 1 hour | Rapid wakefulness improvement |
| Duration | 9 hours | Covers full daytime/work period |
| MWT Improvement | Significant enhancement | Objective measure of wakefulness maintenance |
| ESS Score (12 weeks) | -7.7 points (150mg group) | Clinically meaningful reduction in sleepiness |
| Symptom Improvement | ~90% of patients reported improvement | High responder rate |
| Long-term Efficacy (1 year) | >96% sustained improvement | Durable benefit with continued treatment |
Safety & Tolerability Profile
- Adverse Events: Mostly mild-to-moderate, occurring within first week, subsiding over time
- Nighttime Sleep: Does not affect nighttime sleep architecture
- Cardiovascular: Minimal impact on blood pressure in OSA patients
- Discontinuation: No rebound sleepiness after treatment cessation
- Validation: Positive conclusions confirmed by Chinese Phase 3 clinical study
Commercial Rights & Partnership
| Agreement | Details |
|---|---|
| Partner | SK Biopharmaceuticals |
| Deal Signed | November 2021 |
| Territory | Greater China (Mainland, Hong Kong, Macau, Taiwan) |
| Rights | Exclusive development, registration, local production, and commercialization |
| Strategic Value | Leverages SK’s global development data for accelerated China entry |
Market Opportunity & Strategic Outlook
- OSA Prevalence: 180 million adults in China affected by OSA; 60 million experience EDS
- Market Gap: Limited pharmacologic options for OSA‑related EDS; solriamfetol offers first oral non‑stimulant alternative
- Competitive Positioning: Differentiated from modafinil/armodafinil through dual mechanism and longer duration
- Revenue Forecast: Analysts project ¥500‑800 million (US$70‑110 million) peak China sales by 2029
- Next Steps: Pricing negotiations with NHSA; hospital listing campaign Q1 2026
Forward‑Looking Statements
This brief contains forward‑looking statements regarding solriamfetol commercialization timelines, market penetration, and revenue projections. Actual results may differ due to regulatory, competitive, and reimbursement uncertainties.-Fineline Info & Tech
